Search

M2 PRESSWIRE-January 15, 2025-: Retinitis Pigmentosa Pipeline Assessment 2024: Therapies, Clinical Trials, and Key Companies involved by DelveInsight | Biogen, Neurotech, Ionis Pharma, Nacuity Pharma, Allegro Ophthalmics, ID Pharma (C)1994-2025 [...]

M2 PRESSWIRE-January 15, 2025-: Acute Kidney Injury Pipeline Analysis 2024: FDA Approvals, Emerging Therapies, and Key Companies involved by DelveInsight | Astellas Pharma, Amniotics, Guard Therapeutics, RegeneRx Biopharma, Cerenis (C)1994-2025 [...]

M2 PRESSWIRE-January 14, 2025-: Epidermolysis Bullosa Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and Key Companies Involved by DelveInsight | RegeneRx Biopharma, BridgeBio Pharma, Berg Pharma, Holostem Terapie (C)1994-2025 M2 [...]

M2 PRESSWIRE-January 7, 2025-: Ascites Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | YZY Biopharma, Healthgen Biotech, Grifols Therapeutics, Versantis (C)1994-2025 M2 COMMUNICATIONS [...]

M2 PRESSWIRE-December 20, 2024-: Spinal Muscular Atrophy Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and MOA, ROA by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme Corp [...]

M2 PRESSWIRE-November 26, 2024-: Gilead Sciences: Designing Inclusive Clinical Trials in an Effort To Upend the HIV Epidemic (C)1994-2024 M2 COMMUNICATIONS RDATE:26112024 Women - especially teen girls and young women [...]

M2 PHARMA-January 3, 2025-Hanx Biopharmaceuticals reports first patient dosed in Phase 1 clinical trial of HX044 (C)2025 M2 COMMUNICATIONS Chinese biotechnology company Hanx Biopharmaceuticals Co Ltd announced on Thursday the [...]

M2 EQUITYBITES-January 3, 2025-Hanx Biopharmaceuticals reports first patient dosed in Phase 1 clinical trial of HX044 (C)2025 M2 COMMUNICATIONS http://www.m2.co.uk Chinese biotechnology company Hanx Biopharmaceuticals Co Ltd announced on Thursday [...]

M2 PHARMA-December 18, 2024-Hansa Biopharma reports positive Phase 2 imlifidase results (C)2024 M2 COMMUNICATIONS Swedish biopharmaceutical company Hansa Biopharma (STO:HNSA) on Tuesday announced positive full results from the 15-HMedIdeS-09 single [...]

M2 EQUITYBITES-December 18, 2024-Hansa Biopharma reports positive Phase 2 imlifidase results (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk Swedish biopharmaceutical company Hansa Biopharma (STO:HNSA) on Tuesday announced positive full results from the 15-HMedIdeS-09 [...]

NORDIC BUSINESS REPORT-December 3, 2024-Genethon and Hansa Biopharma initiate Phase 2 trial for Crigler-Najjar syndrome (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk Swedish biopharmaceutical company Hansa Biopharma (STO:HNSA) and Genethon, a developer of [...]

M2 EQUITYBITES-December 3, 2024-Genethon and Hansa Biopharma initiate Phase 2 trial for Crigler-Najjar syndrome (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk Swedish biopharmaceutical company Hansa Biopharma (STO:HNSA) and Genethon, a developer of gene [...]

M2 PHARMA-December 3, 2024-Genethon and Hansa Biopharma initiate Phase 2 trial for Crigler-Najjar syndrome (C)2024 M2 COMMUNICATIONS Swedish biopharmaceutical company Hansa Biopharma (STO:HNSA) and Genethon, a developer of gene therapies [...]

M2 PRESSWIRE-October 25, 2024-: Triple Negative Breast Cancer Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | ModernaTX, Inc., OncoTherapy Science, Phoenix Molecular (C)1994-2024 [...]

M2 PRESSWIRE-October 24, 2024-: Advanced Renal Cell Carcinoma Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Molecure S.A., Daiichi Sankyo, Janux Therapeutics (C)1994-2024 [...]

M2 PRESSWIRE-October 22, 2024-: Primary Hyperoxyaluria Clinical Trials 2024: FDA Approvals, Medication, Treatment Market, Therapies, MOA, ROA, Companies by DelveInsight | Dicerna Pharma, Allena Pharma, Genentech, Biocode, Alnylum (C)1994-2024 M2 [...]

M2 PRESSWIRE-October 21, 2024-: Spinocerebellar Ataxias Pipeline Review 2024: Clinical Trials Update and Key Companies Involved by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma, Anima Biotech Inc [...]

M2 PRESSWIRE-October 15, 2024-: Pressure Ulcers Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Xantho Biotechnology, Biocomposites Ltd, RegeneRx Biopharma, B. Braun (C)1994-2024 [...]

M2 PRESSWIRE-October 9, 2024-: Hepatitis B Virus Infection Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, MOA, ROA, and Companies by DelveInsight (C)1994-2024 M2 COMMUNICATIONS RDATE:09102024 Hepatitis B Virus [...]

M2 PRESSWIRE-October 7, 2024-: Frontotemporal Dementia Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Alector, Oncolys BioPharma, Denali Therapeutics, Passage Bio (C)1994-2024 M2 [...]

M2 PRESSWIRE-October 4, 2024-: Hepatocellular Carcinoma Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA and Companies by DelveInsight (C)1994-2024 M2 COMMUNICATIONS RDATE:04102024 Hepatocellular Carcinoma companies [...]

M2 PRESSWIRE-October 2, 2024-: Multiple Sclerosis Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, MOA, ROA by DelveInsight | Biogen, Immune Response BioPharma, Celgene, Novartis, Sanofi, Actelion, Bayer, Acorda (C)1994-2024 M2 [...]

M2 PRESSWIRE-October 2, 2024-: Irritable Bowel Syndrome Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA, ROA by DelveInsight | P4 Microbiome, Biomica, Invea Therapeutics, RaQualia Pharma, RedHill Biopharma (C)1994-2024 M2 [...]

M2 PRESSWIRE-October 1, 2024-: Alpha Thalassemia Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, MOA, ROA by DelveInsight | Genmedicn Biopharma Ltd., Bristol-Myers Squibb, Agios Pharma (C)1994-2024 M2 COMMUNICATIONS RDATE:01102024 (Las [...]

M2 PRESSWIRE-August 29, 2024-: T-Cell Lymphoma Pipeline Assessment 2024 | Clinical Trials, Latest Approvals, Treatment Outlook, Competitive Landscape, Key Companies | Soligenix, CStone Pharmaceuticals, Genor Biopharma, Innate Pharm (C)1994-2024 M2 [...]

M2 EQUITYBITES-October 28, 2024-LakeShore Biopharma's Phase III YSJA Rabies Vaccine clinical trial receives Chinese NMPA approval (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk Biopharmaceutical company LakeShore Biopharma Co., Ltd (Nasdaq: LSB) announced on [...]

M2 PHARMA-October 28, 2024-LakeShore Biopharma's Phase III YSJA Rabies Vaccine clinical trial receives Chinese NMPA approval (C)2024 M2 COMMUNICATIONS Biopharmaceutical company LakeShore Biopharma Co., Ltd (Nasdaq: LSB) announced on Friday [...]

M2 EQUITYBITES-October 10, 2024-Pharming initiates Phase II clinical trial for leniolisib in PIDs (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk Biopharmaceutical company Pharming Group N.V. (Euronext Amsterdam:PHARM) (NASDAQ:PHAR) announced on Thursday that it [...]

M2 PHARMA-October 10, 2024-Pharming initiates Phase II clinical trial for leniolisib in PIDs (C)2024 M2 COMMUNICATIONS Biopharmaceutical company Pharming Group N.V. (Euronext Amsterdam:PHARM) (NASDAQ:PHAR) announced on Thursday that it has [...]

M2 EQUITYBITES-September 3, 2024-Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk Vaccine company Valneva SE (Nasdaq:VALN) (Euronext Paris:VLA) and biopharmaceutical company [...]

M2 PRESSWIRE-July 10, 2024-: ANCA Vasculitis Pipeline Insights 2024: Therapies, Clinical Trials, and Clinical Trials by DelveInsight | Vifor Pharma, GlaxoSmithKline, Amgen, Genentech, Pfizer, ChemoCentryx, Biogen (C)1994-2024 M2 COMMUNICATIONS RDATE:10072024 [...]

M2 PRESSWIRE-July 9, 2024-: Urticaria Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Sanofi, Genentech, AstraZeneca, Kiniksa Pharmaceuticals, Ltd, United BioPhar (C)1994-2024 M2 [...]

M2 PRESSWIRE-July 4, 2024-: Primary Hyperoxyaluria Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Dicerna Pharma, Allena Pharma, Genentech, Biocode, Alnylum (C)1994-2024 M2 [...]

M2 PRESSWIRE-July 2, 2024-: Chronic Refractory Cough Pipeline Analysis 2024: FDA Approvals and Emerging Therapies by DelveInsight | Genentech, Trevi Therapeutics, Guangdong Hengrui Pharma, Ltd, Bellus Health, Merck (C)1994-2024 M2 [...]

M2 PRESSWIRE-July 1, 2024-: Multiple Sclerosis Clinical Trials Assessment 2024: FDA Approvals, Clinical Trials, Therapies, MOA, ROA and Companies by DelveInsight (C)1994-2024 M2 COMMUNICATIONS RDATE:01072024 Multiple Sclerosis Companies are TG [...]

M2 PRESSWIRE-June 28, 2024-: Hyperoxaluria Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies by DelveInsight | Alnylam Pharma, Genentech, Dicerna Pharma, Pfizer Inc., Zhejiang Tianxin Pharma, Wuxi Further Pharma (C)1994-2024 [...]

M2 PRESSWIRE-June 28, 2024-: Dynavax Technologies commences dosing in Z-1018 phase 1/2 clinical trial (C)1994-2024 M2 COMMUNICATIONS RDATE:28062024 Dynavax Technologies Corporation (Nasdaq: DVAX), a California-based commercial-stage biopharmaceutical company, announced on [...]

M2 PRESSWIRE-June 24, 2024-: Ulcerative Colitis Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight (C)1994-2024 M2 COMMUNICATIONS RDATE:21062024 DelveInsight's, 'Ulcerative Colitis Pipeline Insight 2024' report provides [...]

M2 PRESSWIRE-June 21, 2024-: Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insights | Alexza Pharma, Xenon Pharma, GW Pharma, Equilibre Biopharma, Takeda Pharma, Abide therapeutics, Otsuka pharma (C)1994-2024 [...]

M2 PRESSWIRE-June 19, 2024-: Spinocerebellar Ataxias Pipeline Drugs Analysis Report (2024 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Biogen Inc, Ionis Pharma, BioXcel Corp, Celavie Biosciences [...]

M2 PRESSWIRE-June 19, 2024-: Glioblastoma Multiforme Pipeline Insights 2024 | Clinical Trials, Latest Approvals, Treatment Outlook, Therapies, Companies | Genentech, Merck, Daiichi Sankyo, VBL Therapeutics, Diffusion Pharma (C)1994-2024 M2 COMMUNICATIONS [...]

M2 PRESSWIRE-June 18, 2024-: Myelofibrosis Pipeline Insights 2024 | Clinical Trials, Latest Approvals, Treatment Options, Therapies, Key Companies | Geron Corporation, Merck, Telios Pharma, Ryvu Therapeutics SA, Taiga Biotechnolo (C)1994-2024 [...]

M2 PRESSWIRE-June 14, 2024-: Hypoglycemia Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Amphastar Pharma, Eiger BioPharma, Eli Lilly, Novo Nordisk, Xeris Pharma [...]

M2 PRESSWIRE-June 13, 2024-: Acute Myeloid Leukemia Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Novartis AG, Genmab AS, Sanofi, Teva Pharma, Pfizer, [...]

M2 PRESSWIRE-June 10, 2024-: Marginal Zone Lymphoma Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Beigene, InnoCare Pharma, Hutchmed, Incyte, Innovent, MorphoSys (C)1994-2024 [...]

M2 PRESSWIRE-June 10, 2024-: Ascites Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | YZY Biopharma, Healthgen Biotech, Grifols Therapeutics, Versantis (C)1994-2024 M2 [...]

M2 PRESSWIRE-June 10, 2024-: Ankylosing Spondylitis Pipeline Drugs Analysis Report (2024 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Pfizer, UCB Biopharma, Fresenius Kabi, Shanghai Henlius (C)1994-2024 [...]

M2 PRESSWIRE-June 7, 2024-: Fibromyalgia Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Tonix Pharma, UCB Biopharma SRL, GlaxoSmithKline, Astellas Pharma (C)1994-2024 [...]

M2 PRESSWIRE-June 7, 2024-: Antibody-drug Conjugates in Oncology Pipeline Analysis 2024: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight (C)1994-2024 M2 [...]

M2 PRESSWIRE-June 7, 2024-: Checkpoint Inhibitors Clinical Trials Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight (C)1994-2024 M2 COMMUNICATIONS RDATE:07062024 Checkpoint Inhibitors companies [...]